Clinical Report: Drooling Flags Severe Dermatomyositis
Overview
Drooling in adults with dermatomyositis may indicate advanced disease and increased risk of fatal complications. A case series revealed that patients with drooling experienced progressive disease despite aggressive immunosuppressive therapy, leading to poor outcomes.
Background
Dermatomyositis is a rare idiopathic inflammatory disease characterized by proximal muscle weakness and skin manifestations. Dysphagia is a known complication, and drooling has been infrequently documented, yet may reflect severe oropharyngeal muscle involvement. Recognizing drooling as a potential marker for advanced disease is crucial for timely intervention and management.
Data Highlights
No numerical data available in the article.
Key Findings
- Drooling (sialorrhea) may signal advanced dermatomyositis with severe oropharyngeal involvement.
- All three patients in the case series developed dysphagia and drooling, leading to aspiration pneumonia and sepsis.
- Despite high-dose corticosteroids and combination therapies, patients experienced progressive disease and ultimately died.
- Muscle biopsies showed severe pathologic changes, including atrophy and fibrosis.
- Repeat muscle biopsy may be warranted when clinical suspicion remains high despite normal initial findings.
- Comprehensive myositis antibody panels are recommended to guide prognosis and treatment intensity.
Clinical Implications
Clinicians should be vigilant for drooling in patients with dermatomyositis as it may indicate advanced disease and a higher risk of complications. Early intervention and aggressive treatment strategies, including immunomodulatory therapy, are essential to manage dysphagia and prevent aspiration.
Conclusion
Drooling in dermatomyositis is a critical clinical sign that may reflect severe disease progression and necessitates prompt evaluation and management to mitigate life-threatening risks.
References
- Clinical Rheumatology, 2023 -- Early detection and intervention in dermatomyositis: current evidence and clinical implications
- Clinical Rheumatology, 2022 -- Cardiac Manifestations in Dermatomyositis Associated with Anti-MDA5 Antibodies: A Review of Case Studies
- Clinical Rheumatology, 2023 -- MDA5-associated juvenile dermatomyositis and interstitial lung disease from rapidly progressive to silent: a report of three cases in South African children and a review of the literature
- Clinical Rheumatology, 2019 -- Widespread pruritic erythema as a clinical feature in dermatomyositis linked to anti-SAE antibodies: a case study and review of existing literature
- Drooling as a Red Flag: Insights From a Case Series in Severe Dermatomyositis With Literature Review, EBSCOhost, 2025
- Trial of Intravenous Immune Globulin in Dermatomyositis - PubMed, 2023
- ERS/EULAR clinical practice guidelines for connective tissue disease-associated interstitial lung disease - PubMed, 2023
- Drooling as a Red Flag: Insights From a Case Series in Severe Dermatomyositis With Literature Review. | EBSCOhost
- Trial of Intravenous Immune Globulin in Dermatomyositis - PubMed
- ERS/EULAR clinical practice guidelines for connective tissue disease-associated interstitial lung disease developed by the task force for connective tissue disease-associated interstitial lung disease of the European Respiratory Society (ERS) and the European Alliance of Associations for Rheumatology (EULAR) Endorsed by the European Reference Network on rare respiratory diseases (ERN-LUNG) - PubMed
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
